VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Supernus Pharmaceuticals, Inc. (SUPN) Total Return Calculator with Dividends Reinvested

Supernus Pharmaceuticals, Inc.

Popular:

The total return for Supernus Pharmaceuticals, Inc. (SUPN) stock is +51.37% over the past 12 months. So far it's down 0.89% this year. The 5-year total return is +60.81%, meaning $10,000 invested in SUPN stock 5 years ago would be worth $16,081 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in SUPN 1 year ago, it would be worth $15,119 today — you'd have gained $5,119.

With Dividends Reinvested$15,119+51.19%

Price Only (No DRIP)$15,119+51.19%

Period2025-05-06 → 2026-05-05

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in SUPN

1Y$15,137+$5,137 (+51.4%)51.4% CAGR

3Y$13,356+$3,356 (+33.6%)10.1% CAGR

5Y$16,081+$6,081 (+60.8%)10.0% CAGR

10Y$31,369+$21,369 (+213.7%)12.1% CAGR

15Y$91,303+$81,303 (+813.0%)15.9% CAGR

20Y$91,304+$81,304 (+813.0%)11.7% CAGR

30Y$91,305+$81,305 (+813.0%)7.7% CAGR

Supernus Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading SUPN total return...

As of 2026-05-06

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-0.89%	—	-0.89%	—	$9,911
1Y	+51.37%	51.37%	+51.37%	—	$15,137
3Y	+33.56%	10.13%	+33.56%	—	$13,356
5Y	+60.81%	9.97%	+60.81%	—	$16,081
10Y	+213.69%	12.11%	+213.69%	—	$31,369
15Y	+813.03%	15.89%	+813.03%	—	$91,303
20Y	+813.04%	11.69%	+813.04%	—	$91,304
30Y	+813.05%	7.65%	+813.05%	—	$91,305

Risk & Highlights

Best Year+92.16%2016

Worst Year-27.62%2019

Max Drawdown-22.60%2025-11-04 → 2025-12-02

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+10.63%	+10.63%	—	+0.41%	+10.2pp
2025	+36.43%	+36.43%	—	+16.64%	+19.8pp
2024	+30.40%	+30.40%	—	+24.00%	+6.4pp
2023	-22.76%	-22.76%	—	+24.81%	-47.6pp
2022	+18.58%	+18.58%	—	-19.95%	+38.5pp

SUPN outperformed the S&P 500 by 22.93pp over the past year (+51.37% vs +28.44%).

Loading summary...

SUPN Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
SUPNSupernus Pharmaceuticals, Inc.	$2.8B	-3.0%	-0.9%	+51.4%	—	+33.6%	+60.8%	+213.7%
PCRXPacira BioSciences, Inc.	$975M	+11.3%	+1.3%	-4.0%	—	-42.2%	-60.0%	-48.2%
ACADACADIA Pharmaceuticals Inc.	$3.8B	+0.1%	-14.5%	+47.6%	—	+1.9%	+15.2%	-17.4%
INVAInnoviva, Inc.	$1.7B	-1.6%	+14.0%	+20.9%	—	+92.8%	+96.3%	+96.4%
PRGOPerrigo Company plc	$1.6B	+9.9%	-14.1%	-49.3%	+4.6pp	-58.0%	-59.4%	-78.5%
LNTHLantheus Holdings, Inc.	$5.6B	+13.1%	+27.6%	-20.5%	—	-8.8%	+284.2%	+3967.3%
HRMYHarmony Biosciences Holdings, Inc.	$1.9B	+16.7%	-13.5%	+7.9%	—	-9.8%	+17.4%	-12.6%
AXSMAxsome Therapeutics, Inc.	$11.4B	+31.4%	+24.8%	+91.5%	—	+202.5%	+283.6%	+1891.6%
NKTRNektar Therapeutics	$1.7B	+12.6%	+93.8%	+716.3%	—	+584.2%	-70.0%	-58.9%
LGNDLigand Pharmaceuticals Incorporated	$4.6B	+14.1%	+22.2%	+118.4%	—	+192.8%	+78.4%	+96.5%
CORTCorcept Therapeutics Incorporated	$5.5B	+25.7%	+34.4%	-30.6%	—	+113.3%	+137.0%	+965.1%

Compare:SUPN vs PCRX SUPN vs ACAD SUPN vs INVA SUPN vs PCRX vs ACAD

About SUPN Dividend Returns

Supernus Pharmaceuticals, Inc. (SUPN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of SUPN over the past year?

Supernus Pharmaceuticals, Inc. (SUPN) delivered a return of 51.37% over the past year. Since SUPN does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in SUPN be worth today?

A $10,000 investment in Supernus Pharmaceuticals, Inc. one year ago would be worth $15,137 today, representing a gain of $5,137.

Q3Does SUPN pay dividends?

Supernus Pharmaceuticals, Inc. (SUPN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For SUPN, the total return equals the price-only return.

Q4Did SUPN beat the S&P 500?

Yes, Supernus Pharmaceuticals, Inc. (SUPN) outperformed the S&P 500 by 22.93 percentage points over the past year. SUPN delivered a total return of 51.37%, compared to the S&P 500's 28.44%. This 22.93pp alpha means investors in SUPN earned more than a passive S&P 500 index fund.

Q5What is SUPN's worst drawdown?

Supernus Pharmaceuticals, Inc. (SUPN) experienced a maximum drawdown of -22.60% over the past year, declining from its peak on 2025-11-04 to its trough on 2025-12-02. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is SUPN's long-term total return over 10, 20, or 30 years?

Here are Supernus Pharmaceuticals, Inc. (SUPN)'s long-term returns with dividends reinvested. Over 10 years, the total return is 213.7% (12.1% CAGR) — $10,000 would have grown to $31,369. Over 20 years: 813.0% total return (11.7% CAGR) — $10,000 → $91,304. Over 30 years: 813.0% total return (7.7% CAGR) — $10,000 → $91,305. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was SUPN's best and worst year?

Supernus Pharmaceuticals, Inc.'s best calendar year was 2016 with a total return of 92.2%. Its worst year was 2019 with a total return of -27.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 119.8 percentage points.